Owkin has licensed its K Pro AI platform and multimodal patient data to Servier, a French pharmaceutical company, to accelerate oncology research. The deal allows Servier’s teams to analyze real-world patient data from Owkin’s MOSAIC network within the K Pro system.
The platform integrates patient data with specialized AI tools to support drug development tasks, including molecule optimization, target discovery, biomarker identification, and clinical trial design. Owkin states the system is trained using real-world patient data and validated through its wet lab research.
Thomas Clozel, Owkin’s co-founder and CEO, called the AI platform a shift in how biopharma operates. “By pairing K Pro with Owkin’s multimodal patient data, Servier’s scientists can investigate the biology of hard-to-treat cancers and reach answers that manual analysis alone cannot deliver,” he said.
Claude Bertrand, Servier’s executive vice president of research and development, added that combining patient data and AI analysis will help researchers generate and test hypotheses faster. “We look forward to applying these capabilities across our oncology research,” he said.
Read Also: WhiteLab Genomics Secures $26 Million Series B
This agreement builds on an existing partnership between Owkin and Servier, which began in 2023. Earlier this year, Owkin identified potential biomarker-defined patient subgroups for a Servier oncology drug candidate, prompting Servier to assess those findings using Phase 2 clinical trial data.
Owkin has expanded access to K Pro beyond Servier. In May, AstraZeneca signed a three-year licensing deal to use the platform for research, competitive intelligence, and drug-development decisions. The following month, Sanofi agreed to a five-year license for co-developing biopharma agents through K Pro.
While earlier AI-pharma partnerships often focused on single-use cases, such as drug repurposing or early-stage screening, this deal emphasizes continuous integration of real-world data into hypothesis-driven oncology research. Unlike projects limited to retrospective analysis, Servier’s use of K Pro suggests a shift toward embedding AI-driven insights directly into clinical decision-making, mirroring trends where companies now prioritize dynamic, iterative data models over static datasets.
Owkin’s expansion into oncology aligns with broader industry moves to leverage AI for complex diseases. Earlier this year, Anthropic partnered with Bristol Myers Squibb for enterprise AI applications in drug discovery, while Insilico Medicine secured a $2.75 billion deal with Eli Lilly for AI-driven molecule design.
